6,643 results on '"glomerulonephritis, iga"'
Search Results
2. Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
3. Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)
4. Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)
5. Study of WAL0921 in Patients With Glomerular Kidney Diseases
6. Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)
7. Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
8. A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
9. A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy
10. Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study (QUIgAN)
11. Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
12. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
13. Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
14. Raman Spectroscopy Diagnosis of Kidney Diseases
15. A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
16. A Study of Probiotics in IgA Nephropathy (Pro-IgAN)
17. Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
18. A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy (SPARTAN)
19. Efficacy and Safety of Telitacicept in IgAN
20. Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)
21. A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
22. Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) (Nefigard-OLE)
23. A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept (ORIGIN EXTEND)
24. A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants with IgAN, LN or C3G
25. Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
26. A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)
27. Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
28. Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients with Primary IgA Nephropathy (NefXtend)
29. IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
30. Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)
31. Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy (LYMFONI)
32. Safety and Efficacy Study of VIS649 for IgA Nephropathy
33. Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
34. Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
35. A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (SPARTACUS)
36. A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
37. Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate At Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? (IA-GRACE-IgANT)
38. Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
39. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)
40. Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)
41. A Study of BION-1301 in Adults With IgA Nephropathy
42. Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
43. Atrasentan in Patients With IgA Nephropathy (ALIGN)
44. Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST)
45. A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
46. A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
47. Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (TCMWINE)
48. A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
49. A Study of Telitacicept in Patients with Primary Immunoglobulin A（IgA） Nephropathy
50. Atacicept in Subjects with IgA Nephropathy (ORIGIN 3)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.